Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men

Abstract

Limited data are available about the role of the serotonin 2B (5-HT2B) receptor in the function of human islets. This study aimed to test whether the 5-HT2B receptor contributes to glucose, insulin, and glucagon homeostasis in humans, utilizing a hereditary loss-of-function gene mutation in the receptor, which causes a 50% reduction in the production of the receptor protein in heterozygotes. This clinical study enrolled participants recruited by newspaper advertisements and from mental status examinations. A cohort of participants from a young Finnish founder population composed of 68 non-diabetic males with a mean age of 30 was divided into groups for comparison based on being a 5-HT2B receptor loss-of-function gene mutation (HTR2B Q20*) heterozygote carrier (n=11) or not (n=57). Serum levels of glucose, insulin, and glucagon were measured in a 5 h oral glucose tolerance test using a 75 g glucose challenge. Insulin resistance, insulin sensitivity, and beta cell activity were calculated using the homeostasis model assessment (HOMA2) and whole body insulin sensitivity index (WBISI), as well as the ratio of glucagon to insulin was noted. The areas under the curves (AUCs) were also determined. Concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured in cerebrospinal fluid (CSF). Covariate adjusted mean score comparisons were applied. Lower glucagon secretion and decreased glucose excursion were observed among HTR2B Q20* carriers as compared with individuals who were homozygotes for the wild-type Q20 allele (controls). No differences in insulin secretion, beta cell activity, insulin resistance, or insulin sensitivity were observed. The glucagon to insulin ratio differed between the HTR2B Q20* carriers and controls. CSF levels of 5-HIAA were similar between groups. Our findings indicate that the 5-HT2B receptor may contribute to the regulation of human glucagon and glucose homeostasis and the interplay between glucagon and insulin secretion.

Key words

glucose - glucagon - serotonin 2B receptor - oral glucose tolerance test - insulin resistance - BMI

• References

• 1 Saunders C, Siuta M, Robertson SD et al. Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. Neurochem Int 2014; 73: 113-121
• 2 Bennet H, Balhuizen A, Medina A et al. Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides 2015; 71: 113-120
• 3 Kim H, Toyofuku Y, Lynn FC et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16: 804-808
• 4 Kim K, Oh CM, Ohara-Imaizumi M et al. Functional role of serotonin in insulin secretion in a diet-induced insulin-resistant state. Endocrinology 2015; 156: 444-452
• 5 Yamada J, Sugimoto Y. The 5-HT(2C/2B) receptor agonist, m-chlorophenylpiperazine, increases plasma glucagon levels in rats. Eur J Pharmacol 2000; 406: 153-157
• 6 Yamada J, Sugimoto Y, Yoshikawa T. p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol 1998; 359: 185-190
• 7 Bennet H, Mollet IG, Balhuizen A et al. Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans. Diabetologia 2016; 59: 744-754
• 8 Bevilacqua L, Doly S, Kaprio J et al. A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature 2010; 468: 1061-1066
• 9 Tikkanen R, Tiihonen J, Rautiainen MR et al. Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon. Transl Psychiatry 2015; 5: e681
• 10 Lechin F, Dijs Bv, Pardey-Maldonado B. Insulin versus glucagon crosstalk: central plus peripheral mechanisms. Am J Ther 2013; 20: 349-362
• 11 Virkkunen M, Rawlings R, Tokola R et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994; 51: 20-27
• 12 World Health Organization . Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: WHO Document Production Services; 2006
• 13 Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2192
• 14 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
• 15 Purves RD. Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm 1992; 20: 211-226
• 16 Allison DB, Paultre F, Maggio C et al. The use of areas under curves in diabetes research. Diabetes Care 1995; 18: 245-250
• 17 Matthews JN, Altman DG, Campbell MJ et al. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235
• 18 Lukaski HC, Johnson PE, Bolonchuk WW et al. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985; 41: 810-817
• 19 American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 3rd revised edn. New York: American Psychiatric Press; 1987
• 20 Spitzer RL, Williams JBW, Gibbon M et al. Instruction Manual for the Structured Clinical Interview (SCID). New York: New York State Psychiatric Institute, Biometrics Research; 1988
• 21 Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24: S7-S14
• 22 Predmore JM, Wang P, Davis F et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 2010; 121: 997-1004
• 23 Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-283
• 24 Tudhope SJ, Wang CC, Petrie JL et al. A novel mechanism for regulating hepatic glycogen synthesis involving serotonin and cyclin-dependent kinase-5. Diabetes 2012; 61: 49-60
• 25 Lee Y, Wang MY, Du XQ et al. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011; 60: 391-397
• 26 Hampson LJ, Mackin P, Agius L. Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs. Diabetologia 2007; 50: 1743-1751
• 27 Agius L. Role of glycogen phosphorylase in liver glycogen metabolism. Mol Aspects Med 2015; 46: 34-45
• 28 Konner AC, Bruning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab 2012; 16: 144-152
• 29 Ustione A, Piston DW. Dopamine synthesis and D3 receptor activation in pancreatic beta-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations. Molecular Endocrinology 2012; 26: 1928-1940
• 30 Lim ET, Wurtz P, Havulinna AS et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet 2014; 10: e1004494